MedAll (@MedAllApp) header
MedAll (@MedAllApp) profile picture

We're on a mission to make great medical education accessible, to every healthcare professional. MedAll is an EBAC accredited provider.

United States
Joined September 2017
Photo by MedAll (@MedAllApp)Photo by MedAll (@MedAllApp)Photo by MedAll (@MedAllApp)Photo by MedAll (@MedAllApp)Photo by MedAll (@MedAllApp)Photo by MedAll (@MedAllApp)Photo by MedAll (@MedAllApp)
💡HCP viewpoints wanted We’re exploring care for neurofibromatosis type 1 plexiform neurofibromas (NF1-PN). How confident are you planning MEK inhibitor follow-up covering team responses to new symptoms and assessment of progress toward the patient’s treatment goals?
45%Not confident
9%Slightly confident
36%Moderately confident
9%Very confident
11 votes • 5 days
1
30,228
📣HCPs, can you help? We’re exploring care for neurofibromatosis type 1 plexiform neurofibromas (NF1-PN). How confident are you sharing decisions on surveillance, surgery or targeted therapy when fully resecting symptomatic NF1-PN carries high risk of lasting functional loss?
80%Not confident
0%Slightly confident
20%Moderately confident
0%Very confident
10 votes • 5 days
1
3
39,749
👋Quick question for HCPs We’re exploring care for neurofibromatosis type 1 plexiform neurofibromas (NF1-PN). How confident are you in arranging a pediatric-to-adult handoff that confirms which clinician will oversee NF1-PN surveillance after transfer?
43%Not confident
21%Slightly confident
29%Moderately confident
7%Very confident
14 votes • 5 days
1
38,283
👩‍⚕️HCP perspectives wanted We’re exploring care for neurofibromatosis type 1 plexiform neurofibromas (NF1-PN). How confident are you in deciding when worsening pain or new functional loss in a patient with NF1-PN warrants specialist reassessment before the next scheduled review?
22%Not confident
44%Slightly confident
0%Moderately confident
33%Very confident
9 votes • 5 days
2
26,705
🫀Share your perspective on cardiovascular care! How confident are you in explaining how differences in drug targets and half-lives between FXIa inhibitors and established oral anticoagulants inform whether reversal is needed during major bleeding?
25%Not confident
6%Slightly confident
25%Moderately confident
44%Very confident
16 votes • 4 days
25,395
🩺Cardiology professionals, have your say! How confident are you in judging whether clinical evidence supports FXIa inhibition preventing thrombosis while preserving hemostasis, and supports the same conclusion in AF and non-cardioembolic secondary stroke prevention?
22%Not confident
28%Slightly confident
22%Moderately confident
28%Very confident
18 votes • 4 days
36,147
🧠Cardiovascular and stroke care opinions wanted! How confident are you in individualizing antiplatelet regimens, doses and duration after non-cardioembolic stroke or high-risk TIA, considering recurrence and bleeding risks?
11%Not confident
32%Slightly confident
21%Moderately confident
37%Very confident
19 votes • 4 days
41,712
📢Calling all HCPs working in cardiovascular care! How confident are you in selecting an oral anticoagulant and dose for patients with AF, considering renal function, age, body weight and relevant drug interactions?
47%Not confident
0%Slightly confident
12%Moderately confident
41%Very confident
17 votes • 4 days
1
39,190
💊Your cardiovascular and stroke care insights matter! How confident are you in using likely stroke mechanism, vascular imaging and time since the event to identify patients at high risk of early recurrence after non-cardioembolic stroke or high-risk TIA?
7%Not confident
43%Slightly confident
29%Moderately confident
21%Very confident
14 votes • 4 days
33,587
🥼Cardiovascular care professionals, we’d love to hear from you! How confident are you in using a validated stroke-risk score and assessing modifiable bleeding risks to guide anticoagulation decisions in AF?
23%Not confident
27%Slightly confident
18%Moderately confident
32%Very confident
22 votes • 4 days
1
26,675
📖Cardiovascular and stroke care perspectives wanted! How confident are you in interpreting emerging phase 3 evidence on the benefits and bleeding risks of adding FXIa inhibitors to antiplatelet therapy after non-cardioembolic ischemic stroke or high-risk TIA?
33%Not confident
20%Slightly confident
20%Moderately confident
27%Very confident
15 votes • 4 days
29,056
📊Calling all cardiology care professionals! How confident are you in interpreting emerging phase 3 FXIa inhibitor evidence in AF, balancing stroke or systemic embolism prevention against major bleeding risk versus standard oral anticoagulation?
21%Not confident
21%Slightly confident
21%Moderately confident
36%Very confident
28 votes • 4 days
1
51,823
👋 Care for people with myelofibrosis? Help shape education. How confident are you in explaining why treatments beyond JAK inhibition are being studied alone or with standard care?
53%Not at all
12%Slightly
12%Somewhat
24%Very
17 votes • Final results
1
1
40,075
Don't miss this interactive, case-based CE session modelling real-world decision-making in AUD care with our expert panel: Néstor Szerman, Amandine Luquiens & Khaled Moussawi. Friday 25 September, 12-1pm, Hall 2 Secure your seat today! 👉 app.medalleducation.com/even…
1
2
292
Welcome to the next instalment in our accredited Epithelioid Sarcoma Quick Bits social learning series. Watch this short reel with Dr Seth Pollack on the role of INI1 loss in diagnosing epithelioid sarcoma. Review evidence-based diagnostic considerations, including: 🔬 INI1 loss as a key clue in suspected ES 🧫 Morphology and broad immunohistochemistry in the differential diagnosis 🧬 When SMARCB1 FISH or NGS may support confirmation 🤝 Integrating pathology, imaging, and multidisciplinary review Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below app.medall.org/articles/es-q…
1
129
This is part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below. Watch this short reel with Dr Hannah Abrams on treatment sequencing beyond first-line therapy in epithelioid sarcoma. Review evidence-based considerations for later-line ES management, including: 🔄 Sequencing options after progression on first-line therapy 💊 Anthracycline-, gemcitabine-, and pazopanib-based approaches 📊 Real-world response and progression-free survival data 🤝 Individualizing treatment based on subtype, tolerability, quality of life, and patient goals 🏥 Referral to sarcoma-specialized centers and clinical trial consideration Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below app.medall.org/articles/es-q…
114
Check out the next part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below. Watch this short reel with Dr Hannah Abrams on emerging treatment directions in epithelioid sarcoma. Review evidence-based considerations on evolving approaches, including: 🧬 SMARCB1-deficient biology and rationale for targeted strategies 💊 Anti-angiogenic TKI-based combinations in soft-tissue sarcoma 🛡️ Immunotherapy combinations, including checkpoint blockade approaches 📊 Emerging clinical data and investigational strategies relevant to ES 🏥 Clinical trial consideration in this ultra-rare sarcoma Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below app.medall.org/articles/es-q…
85
This is part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below. Watch this short reel with Dr Hannah Abrams on first-line systemic therapy considerations in advanced epithelioid sarcoma. Review evidence-based treatment considerations, including: 💊 Anthracycline-based chemotherapy as a preferred first-line systemic approach 🧬 Classic vs proximal-type ES and implications for treatment discussions 📊 Real-world data on doxorubicin- and gemcitabine-based regimens 🤝 Individualizing therapy based on disease extent, comorbidities, performance status, and patient goals Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below
69